Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...

LB Pharmaceuticals aims to show that what is old can become new again with a lead drug candidate that’s a modified version of a decades-old schizophrenia medication from Sanofi. The strategy is ...

The Centers for Disease Control and Prevention (CDC) is tracking the growth of the COVID-19 LB.1 variant as it begins to trail KP.3. For a two-week period starting on June 9 and ending on June 22, the ...

LB is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of LB shares has decreased $0.10 since the market last closed. This is a 0.14% drop ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.